Claudio Gasperini

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex^®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Alena Novotná, Jan Mareš, S. Ratcliffe et al. · European Journal of Neurology · 2011 · 464 citations

Medicine, Neurology, Pharmacology +17

Deep gray matter volume loss drives disability worsening in multiple sclerosis

Arman Eshaghi, Ferrán Prados, Wallace Brownlee et al. · Annals of Neurology · 2018 · 439 citations · Full text

Medicine, Neurology, Neuroscience +15

Progression of regional grey matter atrophy in multiple sclerosis

Arman Eshaghi, Razvan Marinescu, Alexandra L. Young et al. · Brain · 2018 · 374 citations · Full text

Medicine, Neurology, Neuroscience +16

The prevalence of pain in multiple sclerosis

Claudio Solaro, Giampaolo Brichetto, Maria Pia Amato et al. · Neurology · 2004 · 284 citations

Medicine, Neurology, Pain Management +13

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

Enrico Millefiorini, Claudio Gasperini, Carlo Pozzilli et al. · Journal of Neurology · 1997 · 271 citations

Life Sciences, Neurology, Pharmacotherapy +9